Trial · NCT05856526
Results by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 68
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| IASI Response, Defined as a Decrease of at Least 50% Absolute Change in IASI Score From Baseline at Week 16 (Yes/No) | Placebo | 0.133 | 95% Confidence Interval 0.037 to 0.379 | proportion of participants | |
| IASI Response, Defined as a Decrease of at Least 50% Absolute Change in IASI Score From Baseline at Week 16 (Yes/No) | Spesolimab | 0.286 | 95% Confidence Interval 0.153 to 0.471 | proportion of participants | |
| Key Secondary Endpoint: IGA Response, Defined as a Decrease of at Least 1-grade Absolute Change in IGA Score From Baseline at Week 16 (Yes/No) | Placebo | 0.400 | 95% Confidence Interval 0.198 to 0.643 | proportion of participants | |
| Key Secondary Endpoint: IGA Response, Defined as a Decrease of at Least 1-grade Absolute Change in IGA Score From Baseline at Week 16 (Yes/No) | Spesolimab | 0.357 | 95% Confidence Interval 0.207 to 0.542 | proportion of participants | |
| IGA Score of 0 or 1 at Weeks 4, 8, 12 and 16 (Yes/No) | Placebo | Week 4 | 0.000 | 95% Confidence Interval 0.000 to 0.204 | proportion of participants |
| IGA Score of 0 or 1 at Weeks 4, 8, 12 and 16 (Yes/No) | Spesolimab | Week 4 | 0.036 | 95% Confidence Interval 0.006 to 0.177 | proportion of participants |
| IGA Score of 0 or 1 at Weeks 4, 8, 12 and 16 (Yes/No) | Placebo | Week 8 | 0.000 | 95% Confidence Interval 0.000 to 0.204 | proportion of participants |
| IGA Score of 0 or 1 at Weeks 4, 8, 12 and 16 (Yes/No) | Spesolimab | Week 8 | 0.000 | 95% Confidence Interval 0.000 to 0.121 | proportion of participants |
| IGA Score of 0 or 1 at Weeks 4, 8, 12 and 16 (Yes/No) | Placebo | Week 12 | 0.000 | 95% Confidence Interval 0.000 to 0.204 | proportion of participants |
| IGA Score of 0 or 1 at Weeks 4, 8, 12 and 16 (Yes/No) | Spesolimab | Week 12 | 0.036 | 95% Confidence Interval 0.006 to 0.177 | proportion of participants |
| IGA Score of 0 or 1 at Weeks 4, 8, 12 and 16 (Yes/No) | Placebo | Week 16 | 0.000 | 95% Confidence Interval 0.000 to 0.204 | proportion of participants |
| IGA Score of 0 or 1 at Weeks 4, 8, 12 and 16 (Yes/No) | Spesolimab | Week 16 | 0.036 | 95% Confidence Interval 0.006 to 0.177 | proportion of participants |
| IASI Response, Defined as a Decrease of at Least 50% Absolute Change in IASI Score From Baseline at Weeks 4, 8, and 12 (Yes/No) | Placebo | IASI response at Week 4 | 0.067 | 95% Confidence Interval 0.012 to 0.298 | proportion of participants |
| IASI Response, Defined as a Decrease of at Least 50% Absolute Change in IASI Score From Baseline at Weeks 4, 8, and 12 (Yes/No) | Spesolimab | IASI response at Week 4 | 0.250 | 95% Confidence Interval 0.127 to 0.434 | proportion of participants |
| IASI Response, Defined as a Decrease of at Least 50% Absolute Change in IASI Score From Baseline at Weeks 4, 8, and 12 (Yes/No) | Placebo | IASI response at Week 8 | 0.067 | 95% Confidence Interval 0.012 to 0.298 | proportion of participants |
| IASI Response, Defined as a Decrease of at Least 50% Absolute Change in IASI Score From Baseline at Weeks 4, 8, and 12 (Yes/No) | Spesolimab | IASI response at Week 8 | 0.286 | 95% Confidence Interval 0.153 to 0.471 | proportion of participants |
| IASI Response, Defined as a Decrease of at Least 50% Absolute Change in IASI Score From Baseline at Weeks 4, 8, and 12 (Yes/No) | Placebo | IASI response at Week 12 | 0.133 | 95% Confidence Interval 0.037 to 0.379 | proportion of participants |
| IASI Response, Defined as a Decrease of at Least 50% Absolute Change in IASI Score From Baseline at Weeks 4, 8, and 12 (Yes/No) | Spesolimab | IASI response at Week 12 | 0.286 | 95% Confidence Interval 0.153 to 0.471 | proportion of participants |
| IASI-E Subscore Response, Defined as a Decrease of at Least 50% Absolute Change in IASI-E Subscore at Weeks 4, 8, 12, and 16 (Yes/No) | Placebo | IASI-E subscore response at Week 4 | 0.000 | 95% Confidence Interval 0.000 to 0.204 | proportion of participants |
| IASI-E Subscore Response, Defined as a Decrease of at Least 50% Absolute Change in IASI-E Subscore at Weeks 4, 8, 12, and 16 (Yes/No) | Spesolimab | IASI-E subscore response at Week 4 | 0.250 | 95% Confidence Interval 0.127 to 0.434 | proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05856526/results